ArticleScientific reports2025
Anti-inflammatory effects of Lonicera macranthoides Hand.-Mazz based on Spectrum-effect relationship, network pharmacology and molecular docking technology.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transforming urban parks into comprehensive-health- promoting spaces.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study investigated the anti-inflammatory properties of Lonicera macranthoides and its active component isochlorogenic acid C (ILAC) through an integrated approach combining spectrum-effect relationship analysis, network pharmacology, and molecular docking. Five extracts (S1-S5) were evaluated in LPS-stimulated RAW 264.7 macrophages, with S4 demonstrating the strongest inhibition (45.53 ± 0.23%). HPLC fingerprinting identified 12 characteristic peaks, including ILAC and chlorogenic acid. PLS regression analysis revealed these two compounds were most positively correlated with the observed anti-inflammatory activity. Network pharmacology predicted 113 potential anti-inflammatory targets for ILAC, with PPI network analysis identifying 10 core targets (e.g., CASP3, HIF1A, NF-κB1, TLR4). Molecular docking studies suggested ILAC's potential high binding affinity to these targets (<-5 kcal/mol). Together, these in vitro and in silico analyses indicated that ILAC is a key anti-inflammatory constituent in L. macranthoides, likely acting via multi-target interactions with critical inflammatory mediators. The study provided preliminary molecular-level insights into the traditional use of L. macranthoides for inflammatory conditions and suggested ILAC's potential as a candidate for further anti-inflammatory research. Further in vivo studies are required to substantiate its therapeutic potential and mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.